<?xml version="1.0" encoding="UTF-8"?>
<p id="p0110">Based on the research of Yang et al. (2020),
 <xref rid="bib62" ref-type="bibr">
  <sup>62</sup>
 </xref> the most distinctive comorbidities among the non-survivors of COVID-19 in intensive care units were cerebrovascular disease and diabetes. Similar findings were also observed by Guan et al. (2020)
 <xref rid="bib63" ref-type="bibr">
  <sup>63</sup>
 </xref>; these patients were usually treated with ACE inhibitors or angiotensin II type I receptor blockers (ARB). As mentioned above,
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref> SARS-CoV-2 and SARS-CoV can bind to their target cells through ACE2 receptors expressed by the epithelial cells of lung, intestine and kidney.
 <xref rid="bib64" ref-type="bibr">
  <sup>64</sup>
 </xref> Consequently, careful administration of an ACE inhibitor or ARB for patients with SARS-CoV infection in the absence of ARDS is advised.
</p>
